Generic drugs have saved consumers over $2.4 trillion since 2010, but many pharmaceuticals continue to have little to no competition from generic alternatives. As prescription drug prices continue to hit all-time highs, Brian J. Miller, Ted Cho, and Patrick Dumas show how the Food and Drug Administration’s Priority Review Voucher program could be the key to revitalizing generic drug development. 

In 1990, the Supreme Court in Employment Division v. Smith refused to require religious exemptions to “neutral” and “generally applicable” laws. In a new law review article, William Haun argues that the “text, history, and tradition” of the free exercise clause require the Court to overturn Smith and adopt a new, more expansive conception of religious liberty.

Between 2004 and 2018, the United States lost 2,100 newspapers, leaving vast swathes of the country with little to no media coverage. A new AEI report from Howard Husock explores what businesses and philanthropy can do to return journalism to these “news deserts.”

This week the House passed its version of the National Defense Authorization Act as it continues to consider the other fiscal year 2024 defense funding bills. By diving into the numbers in these proposals, John G. Ferrari and Elaine McCusker reveal the work Congress still needs to do to ensure the enactment of these must-pass bills.

The Biden administration’s Securities and Exchange Commission regulations are removing shareholders’ and companies’ right to question proxy advisers, whose advice dictates many investors’ votes on shareholder proposals. Testifying before the House Committee on Financial Services, Benjamin Zycher warns that this has turned proxy advisers into de facto regulators, free to impose environmental, social, and governance imperatives regardless of their fiduciary duty.